Unlocking the UK’s Biotech Potential

As highlighted by Rushi Sunak during his time in office and in an article released in the Times last week, biotechnology within the Life Sciences arena is rapidly becoming one of the defining industries of our time. Over the next year, we are likely to see breakthroughs such as personalised cancer treatments, cures for rare genetic illnesses, and the routine ability to engineer new DNA sequences capable of tackling resistant threatening bacteria. Analysts expect the global economic impact of biotech to exceed $2 trillion by 2030, reshaping not only healthcare but also major sectors of manufacturing.

However, despite the UK’s rich heritage in scientific research and discoveries, we risk falling behind at a pivotal moment. The UK research base continues to deliver world‑class discoveries from top academics and scientists, yet investment tells a different story: equity financing for UK biotech fell by almost half in 2025, with venture capital activity also dropping sharply. Meanwhile, companies frequently find their innovations cleared for use overseas long before they are authorised domestically, a regulatory mismatch that discourages innovators from staying here.

Yet whilst the UK has increased R&D spending, it cannot compete in investment terms with the world’s largest economies. Instead, we need a more strategic approach for enhanced growth and there is so much fertile soil for it.

The UK hosts over half of Europe’s advanced therapy clinical trials, and the medicines regulator (The MHRA) is introducing a more flexible pathway for approving rare‑disease treatments by authorising overarching techniques rather than necessitating approval for individual products. This shift promises to cut costs and reduce delays.

Further, with unparalleled resources such as the UK Biobank and extensive NHS genomic datasets, Britain has a unique opportunity to build a thriving domestic ecosystem to cure more diseases. Prioritising access to these datasets for UK‑based businesses would strengthen our competitive position and attract global investment.

Yet other areas in the sector, such as AI‑enabled drug discovery, are moving far too slowly. Traditionally, 90 per cent. of drug candidates fail early on, but AI has already doubled success rates and shifted much of the process from the laboratory to the computer. 

What is more, regulatory barriers continue to impede growth. Innovators cannot thrive in a system where bringing a product to market is so uncertain and protracted. If current legislation does not sufficiently enable progress, it must be revised.

Aligning with EU biotech regulations could also be a strategic misstep. The EU’s highly precautionary framework is similarly ill‑suited to a period of rapid innovation. If the UK adopts those standards, we risk undermining our ability to compete globally in this critical sector.

Biotechnology sits at the intersection of two of the UK’s greatest strengths: life sciences and artificial intelligence. There is a clear need to leverage our national data assets, reform outdated regulations, and create a sustainable funding environment to signal that Britain is serious about growth in the Life Sciences sector. 

If you have any questions regarding regulatory requirements or raising finance in the Life Sciences sector, please contact our Health, Care and Life Sciences team. 

This article was written by Katie Carter from our Corporate and M&A team. 

https://www.thetimes.com/business/companies-markets/article/rishi-sunak-biotechnology-uk-zcrm8cblw